Scarica l'app Stockscreener
10.36
8.80%
-1.00
Dopo l'orario di chiusura:
10.38
0.02
+0.19%
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Cell therapy scores year-long benefit in myasthenia gravis, heads to Phase III - The Pharma Letter
US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert - Benzinga
Cartesian math works out nicely in phase IIb MG trial - BioWorld MedTech
Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind - insights.citeline.com
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients - Benzinga
Cartesian Therapeutics Unveils Promising Phase 2b Trial Results - TipRanks
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewswire
Breakthrough: New CAR-T Therapy Maintains 83% Response Rate After 12 Months in Myasthenia Gravis Patients - Stock Titan
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.14 - Defense World
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Expands Cell Therapy Team with Strategic New Hires - Stock Titan
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Leading mRNA Cell Therapy Company Cartesian Takes Center Stage at Needham Healthcare Conference - Stock Titan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Raised by Bank of New York Mellon Corp - Defense World
Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Yahoo
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock - Investing.com India
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock By Investing.com - Investing.com South Africa
Analysts Issue Forecasts for RNAC FY2025 Earnings - Defense World
Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics By Investing.com - Investing.com Canada
Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright - Investing.com Canada
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Cartesian Therapeutics' Market Cap Drops To US$430m Leaving Insiders With Losses - simplywall.st
Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Yahoo Finance
Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger - TipRanks
Cartesian Therapeutics Advances mRNA Therapy Pipeline - TipRanks
Cartesian Therapeutics Inc. (RNAC) reports earnings - Quartz
Cartesian Therapeutics reports FY24 EPS ($4.49) vs. ($49.76) last year - TipRanks
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics, Inc. SEC 10-K Report - TradingView
Cartesian's $214M War Chest Powers Breakthrough Myasthenia Gravis Treatment into Phase 3 - StockTitan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Bought by Rhumbline Advisers - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Average Target Price from Analysts - Defense World
New York State Common Retirement Fund Sells 1,200 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times
Inside Cartesian's Latest Executive Compensation Package: Key Details Revealed - StockTitan
Cartesian Therapeutics Advances Descartes-08 in Clinical Trials - TipRanks
Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday - Defense World
Cartesian Therapeutics to Participate in Multiple Upcoming Investor Conferences in February and March 2025 - Nasdaq
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Mirae Asset Global Investments Co. Ltd. Has $82,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
What is Leerink Partnrs' Estimate for RNAC FY2024 Earnings? - MarketBeat
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - MarketBeat
4.35%
10.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):